Amgen's Q1 2006 earnings call highlighted strong financial performance, with revenue and EPS exceeding expectations.  Management's tone is optimistic about the company's pipeline and future growth, particularly in the oncology sector. The potential impact on the stock price within the next 1â€“2 weeks hinges on the market's reaction to the updated guidance and the legal resolution on Roche's peg-EPO product.
[1]
